Clinical Trials
8 trialsNCT02116530 2025-01-28
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00795769 2017-05-23
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00248547 2017-05-09
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
OHSU Knight Cancer Institute
Phase NA Completed
NCT02979548 2017-01-25
Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy
All India Institute of Medical Sciences
Phase 3 Unknown
NCT00006348 2016-07-06
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00954941 2015-06-25
Ondansetron Versus Aprepitant Plus Ondansetron for Emesis
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00499668 2013-04-02
Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer
Vanderbilt-Ingram Cancer Center
Phase NA Withdrawn
NCT01031498 2012-08-07
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
M.D. Anderson Cancer Center
Phase 2 Completed